Cranial Nerve-VI Palsy as the Main Clinical Manifestation of Neurosarcoidosis.

INTRODUCTION: Sarcoidosis is a chronic, systemic, inflammatory disorder that is characterized by the formation of noncaseating granulomas. Patients may present with cranial nerve palsy, paresthesia, paresis, pyramidal signs, progressive cognitive decline, urinary retention, seizures, or hypothalamic-pituitary syndrome. Although the diagnosis of neurosarcoidosis can be challenging, neurological manifestations of sarcoidosis occur more frequently than previously described. CASE REPORT: A 23-year-old African American man presented to our emergency department with diplopia, which was worsened on left horizontal gaze. On the day of admission, he had a witnessed seizure. Laboratory studies were significant only for mild leukopenia and erythrocyte sedimentation rate of 17 mm/h. Brain magnetic resonance imaging revealed diffuse thickening and enhancement of the dura, mild mass effect, and soft tissue enhancement through the foramen rotundum and left orbital apex. The patient was treated with intravenous methylprednisolone and discharged on 60 mg oral prednisone daily followed by a taper over a 2-month period. CONCLUSIONS: Our case demonstrates that mild neurological deficits can be the initial presentation of neurosarcoidosis in patients with undiagnosed or proven sarcoidosis.

Disorders of the Autonomic Nervous System after Hemispheric Cerebrovascular Disorders: An Update.

Autonomic and cardiac dysfunction may occur after vascular brain injury without any evidence of primary heart disease. During acute stroke, autonomic dysfunction, for example, elevated arterial blood pressure, arrhythmia, and ischemic cardiac damage, has been reported, which may hinder the prognosis. Autonomic dysfunction after a stroke may involve the cardiovascular, respiratory, sudomotor, and sexual systems, but the exact mechanism is not fully understood. In this review paper, we will discuss the anatomy and physiology of the autonomic nervous system and discuss the mechanism(s) suggested to cause autonomic dysfunction after stroke. We will further elaborate on the different cerebral regions involved in autonomic dysfunction complications of stroke. Autonomic nervous system modulation is emerging as a new therapeutic target for stroke management. Understanding the pathogenesis and molecular mechanism(s) of parasympathetic and sympathetic dysfunction after stroke will facilitate the implementation of preventive and therapeutic strategies to antagonize the clinical manifestation of autonomic dysfunction and improve the outcome of stroke.

Trends in Outcome and Hospitalization Cost among Adult Patients with Acute Ischemic Stroke in the United States.

INTRODUCTION: New treatments for acute ischemic stroke (AIS) have been introduced and are expected to improve patients' overall outcomes. We assessed the impact of new therapeutic strategies on outcome and cost of hospitalization among adult patients with AIS in the United States. METHODS: Patients with AIS admitted in the United States in 1993-1994 and 2006-2007 were listed using the Nationwide Inpatient Survey database. We determined the rates of occurrence, hospitalization outcomes, and mean hospital charges for all patients. We further analyzed these variables in the ventilated and nonventilated patients. RESULTS: We identified 386,043 patients with AIS admitted in the United States in 1993-1994 and 749,766 patients in 2006-2007. The length of hospitalization was significantly higher in 1993-1994 compared with 2006-2007: 6.9 ± 4.2 days versus 4.66 ± 3 days, respectively. In-hospital mortality rate was 8.9% in 1993-1994 and 5.6% in 2006-2007 (P < 0.0001). There was a significant increase in mean hospital charges in 2006-2007 compared with 1993-1994 ($21,916 ± $14,117 versus $9,646 ± $5,727). The length of hospitalization was significantly shorter in 2006-2007 in nonventilated patients. There was a significant increase in mean hospital charges in 2006-2007 compared with 1993-1994 in both ventilated ($81,528 ± $64,526 versus $25,143 ± $17,172, P<0.0001) and nonventilated patients ($21,085 ± $13,042 versus $10,000 ± $6,300, P<0.0001). The mortality rate was significantly lower in 2006-2007 in both subgroups: 46.5% versus 59.8% in ventilated patients and 4.2% versus 8.2% in nonventilated patients (P < 0.0001). CONCLUSION: Our study suggests that new therapeutic strategies have improved outcomes and increased cost of hospitalization among adult patients with AIS in the United States over a period of 13 years. The hospitalization cost was significantly higher in the ventilated and nonventilated patients in 2006-2007, which may reflect the impact of new therapeutic strategies, the availability of more intensive care units and stroke centers, and the lower mortality rate in this time period.